---
schema_version: "secwatch.filing_event.v1"
accession: "0001778922-26-000004"
form_type: "8-K"
ticker: "SGP"
cik: "0001778922"
company_name: "SpyGlass Pharma, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:04:03.998575+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SpyGlass Pharma reports positive 12-month Phase 1/2 results for BIM-IOL System; 97% off topical drops

## Summary
- 97% of patients on BIM-IOL System were free from all topical IOP-lowering medications at 12 months.
- Mean IOP reduction from baseline: 34% (78-mcg) and 42% (39-mcg) vs 35% for timolol control.
- 100% of BIM-IOL patients achieved BCDVA of 20/32 or better; mean BCDVA equivalent to 20/20.
- Adverse event rates similar across groups (36.7%-43.5%); no serious ocular AEs observed.
- Company is enrolling two identical registrational Phase 3 trials of the 78-mcg dose (initiated Jan 2026).

## SEC filing metadata
- accession: 0001778922-26-000004
- form_type: 8-K
- ticker: SGP
- cik: 0001778922
- company_name: SpyGlass Pharma, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000004/0001778922-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1778922/000177892226000004/sgp-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001778922-26-000004
- JSON: https://secwatch.observer/filing/0001778922-26-000004.json
- Plain text: https://secwatch.observer/filing/0001778922-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.